---
title: CRO Daily News — August 4, 2026
slug: daily-news-2026-08-04-cro
site: cro
post_kind: news
byline: BioBM
description: August 4 CRO daily: Niagen Bioscience Engages Evotec for IND-Enabling Studies on NB4168 Ataxia Telangiectasia Candidate — Evotec's INDiGO platform at Verona…
canonical_url: https://www.cro.directory/posts/daily-news-2026-08-04-cro
published_at: 2026-08-04T23:59:40.312Z
last_updated: 2026-08-05T00:00:48.778Z
---

### Niagen Bioscience Engages [Evotec](/companies/evotec) for IND-Enabling Studies on NB4168 Ataxia Telangiectasia Candidate
- Niagen Bioscience selected [Evotec](/companies/evotec) to conduct pharmacokinetic, pharmacodynamic, and bioanalytical validation studies for NB4168, an oral small-molecule candidate for rare pediatric Ataxia Telangiectasia.
- Work will be performed at Evotec's Verona, Italy campus via its INDiGO integrated preclinical-to-clinical platform, generating data to support FDA IND submission.
- NB4168 has secured FDA Rare Pediatric Disease and EMA Orphan Medicinal Product designations; nonclinical studies show substantially higher blood exposure versus NR chloride.

**Operational Impact**

[Evotec](/companies/evotec)'s INDiGO platform at Verona expands its integrated preclinical-to-IND service footprint for rare-disease sponsors, demonstrating demand for consolidated early-phase development capacity in Europe.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cro-news/niagen-bioscience-selects-evotec-as-cro-to-advance-ind-enabling-development-for-nb4168-in-ataxia-telangiectasia)*

## References

1. [PharmaSource RSS — Niagen Bioscience Engages Evotec for IND-Enabling Studies on NB4168 Ataxia Telangiectasia Candidate](https://pharmasource.global/content/news/cro-news/niagen-bioscience-selects-evotec-as-cro-to-advance-ind-enabling-development-for-nb4168-in-ataxia-telangiectasia)

Source: https://www.cro.directory/posts/daily-news-2026-08-04-cro